PainReform (NASDAQ:PRFX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of PainReform (NASDAQ:PRFX) to a sell rating in a report published on Saturday morning.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of PainReform in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

PainReform Price Performance

Shares of PainReform stock opened at $1.00 on Friday. PainReform has a 12-month low of $0.97 and a 12-month high of $17.95. The stock has a market cap of $870,000.00, a P/E ratio of -0.00 and a beta of 1.06. The business’s 50 day moving average is $1.45 and its 200-day moving average is $2.27.

PainReform Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.